Back to Search Start Over

The SINE Compound KPT-350 Blocks Dystrophic Pathologies in DMD Zebrafish and Mice.

Authors :
Hightower RM
Reid AL
Gibbs DE
Wang Y
Widrick JJ
Kunkel LM
Kastenschmidt JM
Villalta SA
van Groen T
Chang H
Gornisiewicz S
Landesman Y
Tamir S
Alexander MS
Source :
Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2020 Jan 08; Vol. 28 (1), pp. 189-201. Date of Electronic Publication: 2019 Sep 03.
Publication Year :
2020

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked muscle wasting disease that is caused by the loss of functional dystrophin protein in cardiac and skeletal muscles. DMD patient muscles become weakened, leading to eventual myofiber breakdown and replacement with fibrotic and adipose tissues. Inflammation drives the pathogenic processes through releasing inflammatory cytokines and other factors that promote skeletal muscle degeneration and contributing to the loss of motor function. Selective inhibitors of nuclear export (SINEs) are a class of compounds that function by inhibiting the nuclear export protein exportin 1 (XPO1). The XPO1 protein is an important regulator of key inflammatory and neurological factors that drive inflammation and neurotoxicity in various neurological and neuromuscular diseases. Here, we demonstrate that SINE compound KPT-350 can ameliorate dystrophic-associated pathologies in the muscles of DMD models of zebrafish and mice. Thus, SINE compounds are a promising novel strategy for blocking dystrophic symptoms and could be used in combinatorial treatments for DMD.<br /> (Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1525-0024
Volume :
28
Issue :
1
Database :
MEDLINE
Journal :
Molecular therapy : the journal of the American Society of Gene Therapy
Publication Type :
Academic Journal
Accession number :
31628052
Full Text :
https://doi.org/10.1016/j.ymthe.2019.08.016